Betta
In May 2023, C4T and Betta Pharmaceuticals entered into a strategic collaboration to develop CFT8919 in China, Hong Kong, Macau and Taiwan. Under the terms of the agreement, C4T is eligible for up to $357 million in potential milestones plus royalties on net sales.
Partner with Us
Interested in partnering with us to leverage our MonoDAC® and BiDAC® research and development capabilities to design molecular glues, heterobivalent degraders or degrader antibody conjugates (DACs)?
Email Us To Collaborate